Big Pharma will have $500 billion to spend in 2022 and is hungry for M&A. Here are the 10 biotechs analysts say are takeover targets.

[unable to retrieve full-text content]Analysts and investors think drug companies could spend up to $1.6 trillion on M&A this year. Here are the 10 companies they agree are up for grabs.